CLINICAL TRIALS PROFILE FOR MEMANTINE HYDROCHLORIDE

505(b)(2) Clinical Trials for memantine hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT01189214 ↗	Psychopharmacotherapy in Multiple Substances Abuse	Completed	National Institutes of Health (NIH)	Phase 3	2009-03-01	Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
New Indication	NCT01189214 ↗	Psychopharmacotherapy in Multiple Substances Abuse	Completed	National Cheng-Kung University Hospital	Phase 3	2009-03-01	Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
New Indication	NCT01261741 ↗	Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems	Completed	Merz Pharmaceuticals GmbH	Phase 2	2010-11-01	In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.

All Clinical Trials for memantine hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000867 ↗	A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1996-12-01	The purpose of this study is to determine the safety and effectiveness of memantine, an experimental drug, in improving AIDS dementia complex (ADC). The symptoms of ADC can be improved with zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, and the effectiveness of ZDV seems to decrease during the second and third years of therapy. The effectiveness of other antiretroviral drugs as treatment for ADC is not known, so it is important to explore alternative therapies.
NCT00001344 ↗	Dextromethorphan Versus Placebo for Neuropathic Pain	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1993-03-01	In our current clinical trial, we are comparing the effects of two NMDA receptor antagonists to placebo in patients with painful distal symmetrical diabetic neuropathy or post-herpetic neuralgia. The treatments in this three-period crossover study are dextromethorphan, up to 920 mg/day (about 8 times the antitussive dose), memantine, 30-50 mg/day, and placebo. Memantine is an NMDA antagonist used in Europe to treat Parkinson's disease and Alzheimer's disease. The underlying hypothesis, based on studies of painful neuropathies in animal models, is that neuropathic pain is caused largely by sensitization of central nervous system neurons caused by excitatory amino acid neurotransmitters, acting largely through NMDA receptors. A previous small trial of dextromethorphan suggested efficacy in diabetic neuropathy pain. The study requires one visit to the NIH outpatient Pain Research Clinic, and consists of three 9-week treatment periods. Patients who respond to one of the medications will be invited to participate in further controlled studies of the medication followed by up to several years of open-label treatment under continued observation.
NCT00040261 ↗	Clinical Trial of Memantine for Major Depression	Completed	National Institute of Mental Health (NIMH)	Phase 3	2002-06-01	The purpose of this study is to determine the safety and effectiveness of the drug memantine for treating major depression. Major depression is a serious public health concern that contributes to significant morbidity and mortality. Despite the availability of a wide range of antidepressant drugs, a proportion of patients with major depression fail to respond to first-line antidepressant treatment, despite adequate dosage, duration, and compliance. Recent studies suggest that the glutamatergic system may play a role in the pathophysiology and treatment of depression. Memantine and other agents which reduce glutamatergic neurotransmission may represent a novel class of antidepressants. The study consists of three phases. In Phase 1, participants will be tapered off all psychiatric medications over a 2-week washout period. In Phase 2, participants will be randomly assigned to receive either memantine or placebo (an inactive pill) three times a day for 8 weeks. Participants who do not respond to the treatment after 8 weeks will be taken off the study and offered standard treatment. Weekly psychiatric evaluations will evaluate treatment response. During Phase 2, participants who respond well to treatment will enter Phase 3, a 16-week continuation phase of either memantine or placebo. Interviews will be conducted every other week in the first month , then monthly thereafter. Participants will have a physical examination, neuropsychological tests, and eye blink tests at baseline and at the end of the study. Pulse, blood pressure, and blood samples will be taken throughout the study. Participants will undergo an electrocardiogram as well as positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain.
NCT00097916 ↗	An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease	Completed	Forest Laboratories	Phase 3	2004-09-01	About 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease. In a recent trial, in the group of patients with moderate to severe AD treated with memantine, there were fewer incidences of agitation. It is hypothesized that memantine will be effective in reducing the symptoms of agitation associated with moderate to severe Alzheimer's Disease.
NCT00097942 ↗	Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients	Completed	Forest Laboratories	Phase 2	2004-08-01	Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving signal to noise ratio and thereby improving cognitive symptoms.

Clinical Trial Conditions for memantine hydrochloride

Condition Name

Condition Name for memantine hydrochloride
Intervention	Trials
Alzheimer's Disease	36
Alzheimer Disease	18
Schizophrenia	12
Dementia	10

Condition MeSH

Condition MeSH for memantine hydrochloride
Intervention	Trials
Alzheimer Disease	67
Disease	27
Dementia	24
Cognitive Dysfunction	23

Clinical Trial Locations for memantine hydrochloride

Trials by Country

Trials by Country for memantine hydrochloride
Location	Trials
United States	657
Canada	60
Spain	31
France	26
Germany	22

Trials by US State

Trials by US State for memantine hydrochloride
Location	Trials
California	48
New York	43
Massachusetts	34
Florida	30
North Carolina	25

Clinical Trial Progress for memantine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for memantine hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	3
PHASE2	10

Clinical Trial Status

Clinical Trial Status for memantine hydrochloride
Clinical Trial Phase	Trials
Completed	152
Recruiting	32
Terminated	23

Clinical Trial Sponsors for memantine hydrochloride

Sponsor Name

Sponsor Name for memantine hydrochloride
Sponsor	Trials
Forest Laboratories	43
H. Lundbeck A/S	15
Massachusetts General Hospital	11

Sponsor Type

Sponsor Type for memantine hydrochloride
Sponsor	Trials
Other	318
Industry	103
NIH	32

Memantine Hydrochloride clinical trials update, market analysis, and forecast (2024–2035)

Last updated: July 28, 2026

Executive summary: Memantine hydrochloride, the NMDA receptor antagonist used for Alzheimer’s disease, is an established, largely off-patent small molecule in most major markets. Current clinical activity concentrates on (1) combination regimens, (2) formulations and dosing optimization, and (3) use expansions in neurodegenerative and cognitive impairment indications rather than new Alzheimer’s disease disease-modifying monotherapy claims. Market growth is primarily driven by patient pool expansion, country-level formulary inclusion, generic volume expansion, and adherence dynamics rather than new exclusivity. Forecasts through 2035 show steady low-to-mid single-digit value growth globally with structurally declining brand contribution and increasing generic share, producing pricing pressure in high-income markets and higher demand elasticity in emerging markets.

Is memantine hydrochloride still in clinical trials in 2025 and what’s the latest status?

Short answer: Yes, but trial velocity is modest versus earlier drug-development eras. Most active studies focus on combination therapies, comparative effectiveness, and real-world aligned endpoints, with a smaller stream of formulation and special population work.

What types of studies dominate current memantine hydrochloride clinical programs?

Across ongoing and recently completed investigations, the pattern skews to:

• Combination regimens (memantine + acetylcholinesterase inhibitors; or add-on to standard-of-care in moderate-to-severe Alzheimer’s).
• Comparative effectiveness and pragmatic designs targeting cognitive scales and caregiver-reported outcomes.
• Cognitive impairment and neurodegeneration extensions (MCI-like syndromes, Parkinson’s disease dementia, vascular cognitive impairment, and other dementias), typically with secondary endpoints mapped to cognition and functional status.
• Formulation and PK/PD optimization: extended-release, bioequivalence-focused work for generics, and alternative administration routes where relevant.

What clinical endpoints are most commonly used?

• Cognition: ADAS-Cog, MMSE/MoCA derivatives, or domain-specific cognitive batteries.
• Function: ADL subscales, caregiver burden instruments, or clinician-rated functional status.
• Global status: CIBIC-plus or similar global impression metrics (where trials maintain Alzheimer’s conventions).
• Safety: discontinuation due to AEs, dizziness/fatigue, headache, and GI effects; falls risk in older cohorts.

How to interpret “activity” given memantine’s mature status

Memantine’s clinical footprint is shaped by:

• High generic penetration: many studies are conducted as bioequivalence or comparative effectiveness work rather than novel MoA registration programs.
• Regulatory endpoint maturity: Alzheimer’s trial designs are standardized, reducing the need for new mechanism-defining studies.
• Sponsor incentives: commercial upside favors lifecycle extensions, line extensions, and market access rather than primary NDA-level innovation.

What does the Orange Book status of memantine hydrochloride look like and why does it matter for clinical development?

Short answer: Memantine hydrochloride is broadly available as generics; Orange Book-style exclusivity is limited or already expired for the core molecule in most jurisdictions, reducing the financial return of “new” development unless it targets formulation differentiation, combination IP, or new indication strategies.

Why Orange Book status changes trial strategy

When composition-of-matter and key therapeutic patents are expired:

• Trials shift toward new combinations, new dosing regimens, novel formulations, or niche populations.
• Registration risk increases for any “pure” Alzheimer’s re-litigation unless a new IP hook or regulatory pathway is present.

Which product-level differentiators keep trials running?

• Extended-release vs immediate-release: adherence and tolerability comparisons.
• Dose titration protocols: reducing discontinuation.
• Local market formulations: pediatric cohorts (where supported), geriatric substudies, and adherence-driven packaging.

How large is the memantine hydrochloride market and what are the main demand drivers?

Executive market view: The memantine market is a mature dementia-care segment with demand tied to Alzheimer’s prevalence, diagnosis rates, payer coverage, and treatment persistence. Value growth is limited by pricing, but volume growth persists due to patient pool expansion.

Where does demand come from?

• Neurology and geriatrics: prescriptions in moderate-to-severe Alzheimer’s disease.
• Combination prescribing: memantine is often used with donepezil or other background cholinesterase inhibitors.
• Emerging market penetration: higher diagnosis rates and formulary inclusion increase unit volume.
• Institutional care: nursing homes and long-term care settings improve consistency of prescribing and adherence.

What are the key pricing and access constraints?

• Generic pricing compression in major markets.
• Tender dynamics for hospital supply.
• Reimbursement restrictions tied to disease severity staging.

What is the forecast for memantine hydrochloride market size through 2035 (global and by region)?

Short answer: Expect steady growth in global sales value with significant share held by generics and modest growth in unit volumes. Regional patterns differ: emerging markets expand faster in volume; high-income markets grow slowly and experience stronger pricing pressure.

Base-case trajectory (2024–2035)

• Global value: low-to-mid single-digit CAGR through 2030, softening thereafter as pricing stabilizes but competition remains intense.
• Global volume: low-to-high single-digit CAGR depending on country-level coverage and generic penetration speed.

Regional expectations

• North America & Europe: slow value growth driven by adherence and prevalence; continued generic-led price erosion.
• Asia-Pacific: stronger volume growth from diagnosis expansion; value growth can be more resilient due to less entrenched lowest-price equilibrium.
• Latin America and Middle East & Africa: faster penetration dynamics but higher variability in tendering and local reimbursement.

How many patients use memantine hydrochloride and what does prevalence growth imply?

Short answer: Memantine’s addressable population scales with moderate-to-severe Alzheimer’s prevalence and with diagnosis rates. Prevalence growth plus increasing survival expands the pool treated over time.

Patient pool mechanics

• Prevalence growth increases absolute treated patients.
• Diagnosis rates raise treated-to-prevalence ratio.
• Treatment persistence affects annual dosing continuity, especially in severe disease where discontinuation risk rises.

Which competitive products and brands matter most for memantine hydrochloride?

Short answer: Competition is dominated by generics of memantine hydrochloride, plus branded or branded-equivalent products where local history maintains market share. The main “competitive axis” is not another NMDA antagonist displacing memantine, but rather:

• dosing/formulation preferences,
• combination bundling in Alzheimer’s workflows,
• and payer formulary placement.

What other drugs compete indirectly?

• Other Alzheimer’s therapeutics: anti-amyloid agents (where eligible), cholinesterase inhibitors, and combination regimens that shift treatment sequencing.
• Dementia care alternatives: therapies targeting behavioral symptoms or comorbid conditions reduce memantine monotherapy persistence.

When do memantine hydrochloride exclusivity and generic entry risks end, and what does that mean for pricing?

Short answer: Core exclusivity for memantine hydrochloride is functionally mature; generic entry risks are largely historical in most large markets. The main risk to pricing is ongoing competition among generics and new entrants in specific countries and formulation variants.

What keeps competition active even after exclusivity expires?

• Bioequivalence and abbreviated submissions create continuous entry.
• Formulation-specific differentiation (extended release, different salts/form factors).
• Local manufacturing capacity and tender procurement cycles.

What clinical trial signals should investors and strategics monitor next for memantine?

Short answer: Track combination trials with measurable endpoints, any label expansions tied to new dementia phenotypes, and any formulation programs that target adherence, tolerability, or special populations.

High-signal items

• Randomized or well-powered comparative studies showing clinically meaningful benefit in cognition/function versus standard-of-care.
• Trials in dementia subtypes where memantine is not yet standard, with outcomes that can support regulatory or payer adoption.
• Real-world evidence updates on persistence and discontinuation drivers under current generic market conditions.

Key takeaways

• Memantine hydrochloride is a mature, heavily genericized Alzheimer’s therapy with ongoing clinical activity centered on combinations, pragmatic outcomes, and formulation optimization rather than new MoA-defining innovation.
• Market demand tracks Alzheimer’s prevalence, diagnosis rates, formulary coverage, and adherence dynamics.
• Forecasts to 2035 point to steady global growth dominated by generic share and constrained by pricing pressure in high-income markets.
• The most actionable competitive variable is not exclusivity timing but local tendering, formulation preference, and combination prescribing patterns that determine share and pricing stability.

FAQs

1. Are there any ongoing randomized trials of memantine hydrochloride plus donepezil in 2025?
2. What are the most common adverse events reported for memantine hydrochloride in older Alzheimer’s patients?
3. How does memantine extended-release compare with immediate-release on dosing adherence and tolerability?
4. Does memantine hydrochloride have evidence for use in Parkinson’s disease dementia or other non-Alzheimer’s dementias?
5. What are the main factors that determine payer coverage for memantine hydrochloride across major countries?

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. EMA. (n.d.). European public assessment reports and product information for memantine-containing medicines. European Medicines Agency.
3. ClinicalTrials.gov. (n.d.). Search results for memantine hydrochloride. U.S. National Library of Medicine.